Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 5, 2008, Pages 551-560

  Jin, Yong Nan ^a   Chung, Hye Kyung ^a   Kang, Joo Hyun ^b   Lee, Yong Jin ^a   Kimm, Kwang Il ^a   Kim, Young Joo ^a   Kim, Seunghoo ^a   Chung, June Key ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Alpha fetoprotein promoter; Gene therapy; Hepatocellular carcinoma; Radiotherapy; Sodium iodide symporter

Indexed keywords

ALPHA FETOPROTEIN; COMPLEMENTARY DNA; IODINE 131; PERCHLORATE; RADIOACTIVE IODINE; SODIUM IODIDE I 131; TECHNETIUM 99M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CLONOGENIC ASSAY; DRUG DISTRIBUTION; DRUG TARGETING; DRUG TUMOR LEVEL; ENHANCER REGION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SURVIVAL RATE; TUMOR XENOGRAFT;

ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENHANCER ELEMENTS, GENETIC; GENE THERAPY; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; RATS; TECHNETIUM;

EID: 55849126191     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0467     Document Type: Article

References (35)

1. Colombo M. Hepatocellular carcinoma. J Hepatol 1992;15:225.
2. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis relation to treatment: Study of 850 patients. Cancer 1985;6:918.
3. Lamerz R. Tumour makers in cancer of the liver. Diagn Oncol 1991;1:344.
4. Mohr L, Yoon S-K, Eastman SJ, et al. Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice. Hum Gene Ther 2001;12:799.
5. Nakabayashi H, Koyama Y, Suzuki H, et al. Functional mapping of tissue-specific elements of the human α-fetoprotein gene enhancer. Biochem Biophys Res Commun 2004;318:773.
6. Shin JH, Chung JK, Kang JH, et al. Noninvasive imaging for monitoring of viable cancer cells using a dual-imaging reporter gene. J Nucl Med 2004;45:2109.
7. Chung J-K. Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med 2002;43:1188.
8. Dadachova E, Bouzahzah B, Zuckier LS, et al. Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002;29:13.
9. Shen DHY, Marsee DK, Schaap J, et al. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther 2004;11:161.
10. Kang JH, Chung JK, Lee YJ, et al. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med 2004;45:1571.
11. Dohan O, De La Vieja A, Paroder V, et al. The sodium/ iodide symporter (NIS): Characterization, regulation, and medical significance. Endocr Rev 2003;24:48.
12. Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000;6:871.
13. Hernandez-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. World J Gastroenterol 2006;12:6085.
14. Spitzweg C, O'Connor MK, Bergert ER, et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000;60:6526.
15. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001;8:1524.
16. Cengic N, Baker CH, Schütz M, et al. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2001;90:4457.
17. Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium/iodide symporter gene transfer. Gene Ther 2005;12:272.
18. Chen L, Altmann A, Mier W, et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006;47:854.
19. 99mTc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium/iodide symporter gene expression. Nucl Med Biol 2006;33:575.
20. Gleave M, Hsieh JT, Gao CA, et al. Acceleration of human prostate cancer in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:3753.
21. Smanik PA, Liu Q, Furminger TL, et al. Cloning of human sodium/iodide symporter. Biochem Biophys Res Commun 1996;226:339.
22. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458.
23. Kogai T, Kanamoto Y, Li AI, et al. Differential regulation of sodium/iodide symporter gene expression by nuclear receptor ligands in MCF-7 breast cancer cells. Endocrinology 2005;146:3059.
24. - symporters for radioiodide concentrator gene therapy. J Nucl Med 2000;41:1898.
25. Dwyer RM, Bergert ER, O'Connor MK, et al. Sodium/ iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther 2006;13:60.
26. Dwyer RM, Schatz SM, Bergert ER, et al. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther 2005;12:835.
27. Haberkorn U, Henze M, Altmann A, et al. Transfer of human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001;42:317.
28. Ninomiya T, Mihara K, Fushimi K, et al. Regulation of the α-fetoprotein gene by the isoforms of ATBF1 transcription factor in human hepatoma. Hepatology 2002;35:82.
29. Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium/iodide symporter in prostate cancer cell lines. Cancer Res 1999;59:2136.
30. Kakinuma H, Bergert ER, Spitzweg C, et al. Probasin promoter (ARR2PB)-driven, prostate-specific expression of the human sodium/iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003;63:7840.
31. Faiver J, Clere J, Gerolami R, et al. Long-term radioiodine retention and regression of liver cancer after sodium/iodide symporter gene transfer in Wistar rats. Cancer Res 2004;64:8045.
32. Wenzel A, Upadhyay G, Schmitt TL, et al. Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS. Mol Cell Endocrinol 2003;213:99.
33. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117.
34. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res 2000;301:133.
35. Lee YJ, Chung JK, Kang JH, et al. Wild-type p53 enhances cytotoxic effects of radionuclide in gene therapy using NIS. [abstract] J Nucl Med 2004;45(Suppl):195.